With advancing age, sarcopenia, a decline in muscle strength, begins in the fourth decade and intensifies around age 60. Baseline strength varies with age, with younger individuals having the most strength, middle-aged individuals having moderate strength, and the elderly experiencing the lowest strength (
24). Age-stratified comparisons of motor block characteristics following ISB reveal significant differences between ropivacaine and bupivacaine regarding the onset, depth, and recovery of muscle strength. Ropivacaine (0.5%, 30 mL) demonstrated a moderate motor block with a relatively rapid onset (peak effect at 30 - 45 minutes), leading to muscle strength reductions of 18%, 20%, and 21% from baseline in young, middle-aged, and elderly participants. The time spent to reduce 50% of the baseline MMP was 30 min ± 5 (
24). In contrast, in the bupivacaine 0.5% group, muscle power decreased rapidly across all age groups, with the most pronounced weakness observed in middle-aged and elderly groups (30% and 32%, respectively) (20 ± 5 min) to achieve a loss of half-baseline muscle strength (
25). The young group still held an 18% reduction as observed in ropivacaine, which explains how Klein et al. and Casati et al. (2000) estimate there is no clinical difference in onset and duration (
22,
26). The MMP immediately after injection was more aggressive than ropivacaine (19%), indicating a greater degree of onset of motor block features (
27). Both groups hit a lower point of block at 3 hours after the injection, with a loss of baseline MMP (65%, 67%) for ropivacaine and bupivacaine, respectively (
28). The young age of both groups shows the same pattern of MMP (
29). There is a difference in blocking level across ages, which aligns with a study by Gragasin and Tsui suggesting that aging enhances sensitivity to LAs due to structural and functional changes in peripheral nerves, including decreased myelination and slower nerve conduction velocity (
30). After 12 - 24 hours from injection, muscle power recovery was greatest in the young group, regaining 45% - 60%, respectively, and the same with ropivacaine young group findings (
29), while middle-aged and elderly groups suffered delayed muscle power rescue, reaching 50% of recovery after 24 hours (
31,
32). After one week, MMP recovery was greater with ropivacaine, gaining 80% of muscle power, while it was 70% with bupivacaine. All groups remained > 30% below the baseline effect, aligning with bupivacaine's pharmacological properties, including enhanced sodium channel affinity and lipophilicity (
33).